Delivered for Kellogg's product & consumer science.

1. Mediocre to Memorable
Effectively designing slides for science

2. www.smarttalksuccess.com/s
titcher
featured in:
www.lisabmarshall.com/stitch
er

3. Do you know
what happens
to your attention
during a presentation?

4. The speaker is being introduced
Time
Interest
Low
HighHigh
You’re just settling in…

5. Time
Interest
Low
HighHigh
“Oh, the presentation started!”

6. Time
Interest
Low
HighHigh
“Oh, that reminds me …”
…the mind vacations begin

7. bad delivery
+
unclear organization
+
poorly designed slides

8. Time
Interest
Low
HighHigh
Sleep

9. …and the speaker drones on
and on,
and on,
and on,
and on,
and on,
and on,
and on,
and on,
and on,
and on…

10. Time
Interest
Low
HighHigh
Coma

11. Time
Interest
Low
HighHigh
Coma
…until two magic words

12. Time
Interest
Low
HighHigh
“in conclusion…”

13. Unfortunately
this isn’t far
from the truth!

14. Top 5
Annoyances
(Pardi, 2013)
Top 5 presentation annoyances

15. 72%
Reading slides aloud
(Pardi, 2013)

16. The Redundancy Principle:
Redundant material interferes with learning
(Hoffman, 2006)

17. • Help our consumers make informed
dietary choices through trusted sources
via kelloggsnutrition.com
• Website for healthcare professionals
with latest research/resources for patients
• Topics ranging from breakfast and fiber
to digestive health and weight management
Spreading the Word on Nutrition

18. • Help our consumers make informed
dietary choices through trusted sources
via kelloggsnutrition.com
• Website for healthcare professionals
with latest research/resources for patients
• Topics ranging from breakfast and fiber
to digestive health and weight management
Spreading the Word on Nutrition

19. Spreading the Word on Nutrition

22. We want to help our consumers make informed
dietary choices, and we know health care
professionals are among the most trusted sources
of nutrition information. That is why we launched
kelloggsnutrition.com, a website for health care
professionals, in 2012 and expanded it to more
regions globally in 2013. The website
serves as a resource for health care
professionals who are looking to stay current on
the latest research or who are seeking
resources to share with patients and clients.
The site provides updated summaries of
research on topics ranging from breakfast and
fiber to digestive health and weight
management
Spreading the
Word on Nutrition

23. 51%
Text too small to read
(Pardi, 2013)

24. 48%
Full sentences
(Pardi, 2013)

25. 26%
Poor color choices
(Pardi, 2013)

29. 31%
Overly complex diagrams

30. O O

31. Minimum
Essential
Data

32. Let’s look
at
process

33. Skeletal Defects in PcG
Mutants
Suzuki, et al. (2002) Development 129(18):4171-83
wildtype Mutant 1 Mutant 2 Mutant 3

34. Skeletal Defects in PcG
Mutants
Suzuki, et al. (2002) Development 129(18):4171-83
wildtype Mutant 1 Mutant 2 Mutant 3

35. Skeletal Defects in PcG
Mutants
Suzuki, et al. (2002) Development 129(18):4171-83
wildtype Mutant 1 Mutant 2 Mutant 3

36. (Suzuki, et al. 2002)
Wildtype Mutant
Skeletal defects found in PcG mutants

37. (Suzuki, et al. 2002)
Wildtype Mutant
Skeletal defects found in PcG mutants

38. Is silencing PcG important in mammals?
(Suzuki, et al. 2002)
Wildtype Mutant
Skeletal defects found in PcG mutants

39. main point
per slide
1

40. ORANGE ALERT means
immediate truce

41. Use “billboard” design

42. “Headline” titles and takeaways

43. Guide eyes to important stuff

44. Mix of image and text

45. High contrast color

46. Sans-serif font

47. Assertion-evidence structure(Alley et. al, 2007)

48. Assertion-evidence structure

50. Results (1/4)

51. Photo of mouse with helmet

52. Photo of mouse with helmet

53. Never give up!

54. Helmets save lives???

55. Success =
creativity + determination!

58. Let’s look
at
an example

59. Assertion-evidence structure

60. Assertion-evidence structure

64. Let’s look
at more
examples

65. What leads to motor neuron degeneration
in SMARD1?
3 weeks 4 weeks
Fading Nissl staining suggests
arrest of protein translation

66. How do we detect cross-talk
between PTMs?

67. Re-infestation certain in three years

68. A

70. A a A A
How to make
Choose theRIG
HT
font

71. The quick brown fox...Verdana
The quick brown fox…Arial
The quick brown fox…Tahoma
The quick brown fox...Trebuchet
The quick brown fox…Times New Roman
The quick brown fox...Century Gothic
The quick brown fox…Calibri
The quick brown fox…Comic Sans
The quick brown fox…Georgia
What is the BEST font for science?

72. The quick brown fox...Verdana
The quick brown fox…Arial
The quick brown fox…Tahoma
The quick brown fox...Trebuchet
The quick brown fox…Times New Roman
The quick brown fox...Century Gothic
The quick brown fox…Calibri
The quick brown fox…Comic Sans
The quick brown fox…Georgia
What is the best font for science?What is the BEST font for science?

73. 74
Play with

74. 75
PLAY
EMPHASIS
with text for

75. 76
with text forPlayEMPHASIS
EMPHASIS
EMPHASIS
with text for

77. Use METAPHORICAL images

78. 79

79. 80

80. What leads to motor neuron degeneration
in SMARD1?
3 weeks 4 weeks
Fading Nissl staining suggests
arrest of protein translation

81. 82

82. 83

83. Hot Oats/Porridge/NutriGrain Beverage
Nutrigrain Beverage: With 9.5 grams of protein and
4.2 grams of fiber in 250 mililiters.
Hot Oats:2 Savory versions of Heart to Heart
Oats made with 100 whole grain oats.
Porridge:2 All-Bran Instant Porridge offer 1/3 of
daily fiber requirements and is 2nd hot cereal.

84. Minimum
Essential
Graphs

85. (Principae, 2009)
Example of bad graph
from Jean-Luc Dumount, Principae

86. (Principae, 2009)
Principae pruning process
• Data lines better contrasted
• Non-data lines grey
• Position labels near data
• Relevant ticks marks only

87. (Principae, 2009)
Minimum essential graph
by Jean-Luc Dumount, Principae

88. Let’s look
at examples

89. Platelet activation in WB with KKO agonist
0
2000
4000
6000
8000
10000
12000
14000
16000
Control PF4 ADP 10ul TRAP 6 Convulxin PF4 + KKO
P sel MFI
Annexin MFI
0
20
40
60
80
100
120
Control PF4 ADP 10ul TRAP 6 Convulxin PF4 + KKO
P sel % +
Ann % +

90. What is the relative strength KKO in presence of PF4
compared to other established platelet agonists?
0
2000
4000
6000
8000
10000
12000
14000
16000
0
20
40
60
80
100
120
Control PF4 ADP 10ul TRAP 6 Convulxin PF4 + KKO
Mean fluorescence Percent Positivity
PF4/KKO second to Convulxin
P Sel
P Sel %

91. Bar graph
8
31
17
6
74
56
60 80
18
13
23
15
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Taste Chocolate Flavor Cinnamon Flavor Hardness
Too Much
JAR
Not Enough

93. Minimum
essential
graphs require
“builds”
(sometimes)

94. Meet the PcG Complexes
PRC 2
~600 kDa
RPD3
N55
E(z)
Su(z)12
Esc
Pcl
PRC 1
~ 2MDa
Pc
Psc
Sce
zeste
Scm
Ph
Initiation Maintenance

95. Meet the PcG Complexes
PRC 2
~600 kDa
RPD3
N55
E(z)
Su(z)12
Esc
Pcl
PRC 1
~ 2MDa
Pc
Psc
Sce
zeste
Scm
Ph
Initiation Maintenance
Points speaker made:
• Each protein complex is made up
of multiple distinct subunits
• All subunits are required
• Silencing requires both complexes
(this was the main point)

96. Meet the PcG Complexes
PRC 2
~600 kDa
RPD3
N55
E(z)
Su(z)12
Esc
Pcl
PRC 1
~ 2MDa
Pc
Psc
Sce
zeste
Scm
Ph
Initiation Maintenance

97. Meet the PcG Complexes
PRC 2
~600 kDa
RPD3
N55
E(z)
Su(z)12
Esc
Pcl
PRC 1
~ 2MDa
Pc
Psc
Sce
zeste
Scm
Ph
Initiation Maintenance

98. Meet the PcG Complexes
PRC 2
~600 kDa
RPD3
N55
E(z)
Su(z)12
Esc
Pcl
PRC 1
~ 2MDa
Pc
Psc
Sce
zeste
Scm
Ph
Initiation Maintenance

99. Let’s look
at the
“re-do”

100. PcG complexes PRC1 and PRC2
Multiple distinct sub-units
PRC2PRC1

101. PcG complexes PRC1 and PRC2
All sub-units are required – team effort
PRC2PRC1

102. Both PcG complexes PRC1 and PRC 2
are required for silencing
PRC2PRC1

103. Metabolic dysfunction induced by
post-prandial hypoglycemia facilitates obesity
55
75
95
115
135
155
175
30 60 90 120
Glucose

104. Metabolic dysfunction induced by
post-prandial hypoglycemia facilitates obesity
55
75
95
115
135
155
175
30 60 90 120
Glucose

105. Most cases are hyperinsulinemic
0%
50%
100%
30 60 90 120
Ins/Glu
55
75
95
115
135
155
175
Glucose

106. Resolution of post-prandial hypoglycemia
improves obesity outcomes over 18 mos
55
75
95
115
135
155
175
Glucose
0%
50%
100%
30 60 90 120
Ins/Glu

107. Aversive Olfactory learning
Session 1
Experimental Design
Olfactory
Screening
Set Shock
Baseline
Anxiety
STICSA
Specific
anosmia
State–Trait Inventory for Cognitive and Somatic Anxiety
(Ree et al., 2000)

108. Aversive Olfactory learning
Session 1
Experimental Design
Olfactory
Screening
Set Shock
Baseline
Anxiety
STICSA
Specific
anosmia
State–Trait Inventory for Cognitive and Somatic Anxiety
(Ree et al., 2000)

109. State-Trait inventory for
cognitive and somatic anxiety
Session1
Olfactory
Screening
Set ShockBaseline
Anxiety
STICSA
Specific
anosmia
(Ree et al., 2000)

110. Visual analogous scale used
to collect perceptual ratings
Session1
Olfactory
Screening
Set ShockBaseline
Anxiety
STICSA
Specific
anosmia

111. Visual analogous scale used
to collect perceptual ratings
Session1
Olfactory
Screening
Set ShockBaseline
Anxiety
STICSA
Specific
anosmia

117. Multi-scale dispersal patterns
of Triatoma infestans
Corentin M. Barbu, Karthik Sethuraman, Jen Manne,
Javier E. Quintanila Calderon, Michael Z. Levy
University of Pennsylvania – Universidad Peruana Cayetano-Heredia

118. How we added enzymatic function
to de novo proteins
1. Review analysis of the structure
2. How we created the active site by trimming
side chain residues
3. How we stabilized our design by reengineering
the turn

119. Outline
1. Background: structure
2. Methods: active site
3. Results: our design

120. How we added enzymatic function
to de novo proteins
1. Review analysis of the structure
2. How we created the active site by trimming
side chain residues
3. How we stabilized our design by reengineering
the turn

121. How we added enzymatic function
to de novo proteins
1. Review analysis of the structure
2. How we created the active site by trimming
side chain residues
3. How we stabilized our design by reengineering
the turn

122. How we added enzymatic function
to de novo proteins
1. Review analysis of the structure
2. How we created the active site by trimming
side chain residues
3. How we stabilized our design by reengineering
the turn

123. How we added enzymatic function
to de novo proteins
1. Review analysis of the structure
2. How we created the active site by trimming
side chain residues
3. How we stabilized our design by reengineering
the turn

124. Results (2), Characteristics
CCEB
Variable CC
(N=199)
Any T
(N=118)
P-value
Age 58 (47-70) 60 (51-72) 0.23
Gender 67 (33.7%) 32 (27.1%) 0.22
BMI: <25,
25-30,
>30
59 (29.8%)
54 (27.3%)
85 (42.9%)
37 (31.9%)
45 (38.8%)
34 (29.3%)
0.03
CYP2C9, any *2 or *3 29 (14.9%) 42 (35.6%) <0.001
APOE, any E4 67 (34.2%) 35 (29.7%) 0.40
Vitamin K intake 44 (20-112) 35 (20-85) 0.49

125. Results (2), Characteristics
CCEB
Variable CC
(N=199)
Any T
(N=118)
P-value
Age 58 (47-70) 60 (51-72) 0.23
Gender 67 (33.7%) 32 (27.1%) 0.22
BMI: <25,
25-30,
>30
59 (29.8%)
54 (27.3%)
85 (42.9%)
37 (31.9%)
45 (38.8%)
34 (29.3%)
0.03
CYP2C9, any *2 or *3 29 (14.9%) 42 (35.6%) <0.001
APOE, any E4 67 (34.2%) 35 (29.7%) 0.40
Vitamin K intake 44 (20-112) 35 (20-85) 0.49
Which ?
Which?
What are these?

126. Results (2), Characteristics
CCEB
Variable CC
(N=199)
Any T
(N=118)
P-value
Age 58 (47-70) 60 (51-72) 0.23
Gender 67 (33.7%) 32 (27.1%) 0.22
BMI: <25,
25-30,
>30
59 (29.8%)
54 (27.3%)
85 (42.9%)
37 (31.9%)
45 (38.8%)
34 (29.3%)
0.03
CYP2C9, any *2 or *3 29 (14.9%) 42 (35.6%) <0.001
APOE, any E4 67 (34.2%) 35 (29.7%) 0.40
Vitamin K intake 44 (20-112) 35 (20-85) 0.49
N values?
Percentage of group?
Precision of percentage?
P-values?

127. Results (2), Characteristics
CCEB
Variable CC
(N=199)
Any T
(N=118)
P-value
Ag 58 (47-70) 60 (51-72) 0.23
Gender 67 (33.7%) 32 (27.1%) 0.22
BMI: <25,
25-30,
>30
59 (29.8%)
54 (27.3%)
85 (42.9%)
37 (31.9%)
45 (38.8%)
34 (29.3%)
0.03
CYP2C9, any *2 or *3 29 (14.9%) 42 (35.6%) <0.001
APOE, any E4 67 (34.2%) 35 (29.7%) 0.40
Vitamin K intake 44 (20-112) 35 (20-85) 0.49

128. Results (2), Characteristics
CCEB
Variable CC
(N=199)
Any T
(N=118)
P-value
Age 58 (47-70) 60 (51-72) 0.23
Gender 67 (33.7%) 32 (27.1%) 0.22
BMI: <25,
25-30,
>30
59 (29.8%)
54 (27.3%)
85 (42.9%)
37 (31.9%)
45 (38.8%)
34 (29.3%)
0.03
CYP2C9, any *2 or *3 29 (14.9%) 42 (35.6%) <0.001
APOE, any E4 67 (34.2%) 35 (29.7%) 0.40
Vitamin K intake 44 (20-112) 35 (20-85) 0.49

129. T-allele carriers have
increased risk of CYP2C9 *2 or *3
& decreased risk of elevated BMI
T allele
carriers
(N=118)
Non T-allele
carriers
(N=199)
p value
Avg. Age (years) 60 58
% Male 27% 34%
% CYP2C9 *2 or *3 36% 15% <0.001
% BMI >30 29% 43% 0.03
% APOE4 30% 34%
Avg. Vit.K intake 35 44

130. Minimum
Essential
Data

131. Billboard
Design

132. …from Mediocre

133. O O

134. …to memorable